Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects
Laurence Zitvogel, Guido Kroemer
Laurence Zitvogel, Guido Kroemer
Published July 20, 2009
Citation Information: J Clin Invest. 2009;119(8):2127-2130. https://doi.org/10.1172/JCI39991.
View: Text | PDF
Commentary

Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects

Abstract

Conventional chemotherapeutics may induce immunogenic cancer cell death or stimulate immune effectors via so-called off-target effects. The study by Besch et al. in this issue of the JCI now demonstrates that agents designed to stimulate the innate immune system by activating intracellular pattern recognition receptors can kill cancer cells in a direct, cell-autonomous fashion (see the related article beginning on page 2399). The authors show that ligation of viral RNA sensors, such as RIG-I or MDA-5, by viral RNA mimetics triggers mitochondrial apoptosis in human melanoma cells in an IFN-independent fashion. The data suggest that tumor cell killing and immunostimulation may synergize for optimal anticancer immunochemotherapy.

Authors

Laurence Zitvogel, Guido Kroemer

×

Figure 2

Three mechanisms of immunochemotherapy mediated by single agents.

Options: View larger image (or click on image) Download as PowerPoint
Three mechanisms of immunochemotherapy mediated by single agents. (A) An...
(A) An agent may simultaneously induce tumor cell apoptosis and act as a PAMP, thus activating immunostimulatory PRRs. This is the case for RIG-I and MDA-5 ligands, which, in addition to activating the innate immune system, can kill cancer cells, resulting in a combined immunochemotherapeutic effect. (B) An agent may induce tumor cell death in such a way that dying cells release danger-associated molecular patterns (DAMPs), thereby indirectly activating PRRs in innate immune effectors. For example, anthracyclines induce the exposure and release of several DAMPs on dying tumor cells (17, 18). (C) Alternatively, an anticancer agent may directly kill tumor cells and mediate an immunostimulatory off-target effect on immune cells. For example, imatinib mesylate kills tumor cells that are addicted to constitutively activated tyrosine kinases (such as Bcr/Abl in chronic myeloid leukemia and mutated c-Kit or PDGF-Ra in gastrointestinal sarcoma) at the same time that it activates innate immune effectors through an effect on c-Kit in DCs (19).